Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001419373 | SCV001621628 | likely benign | Nemaline myopathy 2 | 2024-01-21 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002271651 | SCV002555920 | likely benign | not specified | 2022-06-16 | criteria provided, single submitter | clinical testing | Variant summary: NEB c.255C>T alters a conserved nucleotide resulting in a synonymous change. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 6.8e-05 in 248750 control chromosomes, predominantly at a frequency of 0.00039 within the South Asian subpopulation in the gnomAD database. This frequency is not higher than expected for a pathogenic variant in NEB causing Nemaline Myopathy 2 (0.00039 vs 0.0035), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.255C>T in individuals affected with Nemaline Myopathy 2 and no experimental evidence demonstrating its impact on protein function have been reported. A ClinVar submitter (evaluation after 2014) cites the variant as likely benign. Based on the evidence outlined above, the variant was classified as likely benign. |